3 months away from commercial launch of this game changer Amplified ART test (11Jan 2022)
$DISA(532.SG$
This saliva test known as the Parallel Amplified Saliva rapid POint-of-caRe Test (Pasport), is the test that pharmacies throughout the world will soon be using and selling . It is a saliva test kit with a 97% sensitivity when compared to the gold standard PCR a test currently used . The result is available in 15 minutes and is as accurate as the PCR a test . The test was developed in Singapore and is the result of a research collaboration between Duke-NUS Medical School, Singapore General Hospital , Cancer Centre Singapore and the National University of Singapore. An important innovation of the new test is that it can be done at any point in time even after food. It uses nanoparticles to bind to the virus, using an antibody placed at the test line to capture viral proteins, additional ACE2 proteins are used to capture the virus. As the virus becomes more infectious, with greater efficacy to bind to ACE2 , the sensitivity of the test will improve too , it will detect all variants of SARS-Cov-2 . The ease of collecting saliva also makes the test more convenient and preferable for those who find nasal swabs uncomfortable. This may enable us to manage COVID-19 more effectively not only at the point of care, but also in settings such as airports, conventions , football games , concerts and even at home. It’s a game changer no doubt about it . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646336/ Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity https://www.duke-nus.edu.sg/about/media/media-releases/pasport
This saliva test known as the Parallel Amplified Saliva rapid POint-of-caRe Test (Pasport), is the test that pharmacies throughout the world will soon be using and selling . It is a saliva test kit with a 97% sensitivity when compared to the gold standard PCR a test currently used . The result is available in 15 minutes and is as accurate as the PCR a test . The test was developed in Singapore and is the result of a research collaboration between Duke-NUS Medical School, Singapore General Hospital , Cancer Centre Singapore and the National University of Singapore. An important innovation of the new test is that it can be done at any point in time even after food. It uses nanoparticles to bind to the virus, using an antibody placed at the test line to capture viral proteins, additional ACE2 proteins are used to capture the virus. As the virus becomes more infectious, with greater efficacy to bind to ACE2 , the sensitivity of the test will improve too , it will detect all variants of SARS-Cov-2 . The ease of collecting saliva also makes the test more convenient and preferable for those who find nasal swabs uncomfortable. This may enable us to manage COVID-19 more effectively not only at the point of care, but also in settings such as airports, conventions , football games , concerts and even at home. It’s a game changer no doubt about it . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646336/ Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity https://www.duke-nus.edu.sg/about/media/media-releases/pasport
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
GreyZone OP : Penny stock no body wants to short. Last chance to take position at 0.008